HUGIN VICTIS TV

“And when patients choose life over the drug, they are forced to grapple with the heartbreak and stress that accompanies taking on debt just to stay alive.” “Unscrupulous price hikes and games to extend the monopoly have created a horrific choice for cancer patients: the drug or death,” the report stated. In a harshly worded analysis, the report refers to Hugin as “a man who by his own admission is responsible for every cold and calculated price hike.” “By one estimate, the type of unethical games played by Hugin will cost Americans $45 billion through 2026 – just for one drug, Revlimid.”įor Hugin, the worst part of the report is the effect of high drug prices on patients. “Generic drugmakers have accused Celgene of refusing to sell samples for generic analysis, a tactic employed by brand-name drugmakers to delay competition and keep prices high,” the report said. The report also alleges that Hugin exploited loopholes in a federal law to block a “cheaper generic version” of Revlimid from coming to market, and was criticized by Food and Drug Administration Commissioner Scott Gottlieb as “the number one offender in denying samples of drugs for generic testing and development.” During his time as CEO, from 2010 to 2018, the cost of Revlimid doubled. The report claims that the price of a single Revlimid capsule increased by more than 165% since Hugin became Celgene president in 2007, going up from $247.28 to $662.36 when he retired to run for office earlier this year. Hugin is spending some of that money to self-finance his challenge to two-term Democratic U.S.

HUGIN VICTIS TV

The profits off Revlimid made Bob Hugin, the former Celgene chairman and CEO, more than $140 million, according to a report issued today by Patients for Affordable Drugs Action, a Super PAC which is spending a reported $1.5 million on a TV ad that opposes Hugin’s campaign for the United States Senate. We had to refinance our house,” Trapp said about the cost of the drug, which is manufactured by New Jersey-based pharmaceutical giant Celgene. Even with good health insurance, Revlimid costs her nearly $20,000 a year in out of pocket expenses. After chemotherapy and a bone marrow transplant, she was put on Revlimid, a live-saving cancer drug that costs $21,197 a month. Jackie Trapp was diagnosed with multiple myeloma, a terminal but treatable blood cancer in 2015.

Hugin victis